Q4 2023 · 13F-HR
MPM BioImpact LLCholdings as filed
Filed 2024-02-13 · accession 0000950123-24-001863
$427.4M
Reported value
32
Positions
2023-12-31
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 230031106 | CGEM | Cullinan Oncology, Inc. | $77.9M | 18.2% | 7,648,268 | Common | SOLE |
| 462260100 | IOVA | Iovance Biotherapeutics Inc | $26.7M | 6.26% | 3,289,470 | Common | SOLE |
| 68062P106 | OLMA | Olema Pharmaceuticals, Inc. | $26.1M | 6.10% | 1,857,136 | Common | SOLE |
| 374163103 | GERN | Geron Corporation | $22.6M | 5.29% | 10,715,620 | Common | SOLE |
| 46565G104 | 5E7 | iTeos Therapeutics, Inc. | $19.1M | 4.47% | 1,745,943 | Common | SOLE |
| 00166B105 | ALXO | ALX Oncology Holdings Inc. | $18.8M | 4.41% | 1,264,759 | Common | SOLE |
| 61559X104 | MLTX | Moonlake Immunotherapeutics | $17.8M | 4.16% | 294,576 | Common | SOLE |
| 22663K107 | CRNX | Crinetics Pharmaceuticals Inc. | $17.0M | 3.98% | 478,234 | Common | SOLE |
| 48576A100 | — | Karuna Therapeutics Inc | $16.9M | 3.95% | 53,279 | Common | SOLE |
| 457669307 | INSM | Insmed Incorporated | $16.4M | 3.83% | 528,150 | Common | SOLE |
| 23257D103 | CBAYUSD | CYMABAY THERAPEUTICS INC | $14.4M | 3.38% | 611,181 | Common | SOLE |
| 760273102 | RPTX | Repare Therapeutics, Inc. | $12.0M | 2.80% | 1,639,849 | Common | SOLE |
| 45826J105 | NTLA | Intellia Therapeutics, Inc. | $11.7M | 2.73% | 382,598 | Common | SOLE |
| 03152W109 | AM6 | Amicus Therapeutics Inc. | $10.2M | 2.38% | 715,883 | Common | SOLE |
| 75901B107 | RGNX | REGENXBIO Inc. | $9.9M | 2.31% | 549,078 | Common | SOLE |
| 558868105 | MDGL | Madrigal Pharmaceuticals inc | $9.5M | 2.21% | 40,910 | Common | SOLE |
| 86366E106 | GPCR | Structure Therapeutics Inc. | $9.4M | 2.20% | 230,696 | Common | SOLE |
| 05337M104 | — | Avadel Pharmaceuticals PLC | $9.4M | 2.20% | 664,986 | Common | SOLE |
| 61775R105 | MORFUSD | MORPHIC HOLDING INC | $9.3M | 2.19% | 323,742 | Common | SOLE |
| 95075A107 | HOWL | Werewolf Therapeutics, Inc. | $9.2M | 2.16% | 2,388,011 | Common | SOLE |
| 75943R102 | RLAY | Relay Therapeutics Inc. | $9.2M | 2.14% | 832,017 | Common | SOLE |
| 98422E103 | XERS | Xeris Biopharma Holdings Inc | $9.0M | 2.12% | 3,847,232 | Common | SOLE |
| 92539P101 | — | Verve Therapeutics, Inc | $8.9M | 2.08% | 638,163 | Common | SOLE |
| 76155X100 | RVMD | Revolution Medicines, Inc. | $7.8M | 1.83% | 273,408 | Common | SOLE |
| 05464T104 | AXSM | Axsome Therapeutics, Inc. | $7.4M | 1.74% | 93,387 | Common | SOLE |
| 92686J106 | VKTX | VIKING THERAPEUTICS INC | $6.1M | 1.42% | 325,284 | Common | SOLE |
| 00653A107 | ADAPY | Adaptimmune Therapeutics plc | $4.0M | 0.95% | 5,095,912 | Common | SOLE |
| 41358P205 | HARPUSD | Harpoon Therapeutics, Inc. | $3.6M | 0.85% | 319,670 | Common | SOLE |
| 254604101 | IRON | Disc Medicine Inc | $2.9M | 0.68% | 50,000 | Common | SOLE |
| 92790C104 | VRDN | Viridian Therapeutics Inc | $2.2M | 0.51% | 100,000 | Common | SOLE |
| 45790W108 | — | Inozyme Pharma Inc. | $1.4M | 0.32% | 323,813 | Common | SOLE |
| 71722W107 | PHAT | Phathom Pharmaceuticals inc | $639,100 | 0.15% | 70,000 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.